|
gptkbp:instanceOf
|
gptkb:drug
selective estrogen receptor degrader
|
|
gptkbp:administeredBy
|
solution for injection
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L02BA03
|
|
gptkbp:brand
|
gptkb:Faslodex
|
|
gptkbp:CASNumber
|
gptkb:129453-61-8
|
|
gptkbp:chemicalClass
|
steroidal antiestrogen
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to fulvestrant
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
40 days
|
|
gptkbp:hasMolecularFormula
|
C32H47F5O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fulvestrant
|
|
gptkbp:indication
|
postmenopausal women
hormone receptor-positive metastatic breast cancer
|
|
gptkbp:KEGGID
|
D04124
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
estrogen receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
606.77 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
94598
CHEMBL1200969
104741
DB00947
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
nausea
fatigue
injection site pain
hot flashes
|
|
gptkbp:synonym
|
ICI 182,780
|
|
gptkbp:UNII
|
N8SVZ1JF75
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:alpelisib
|
|
gptkbp:bfsLayer
|
5
|